[Form 4] Medpace Holdings, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Medpace Holdings insider transaction summary — An officer and director, Susan E. Burwig, reported a sale of 10,000 shares of Medpace common stock executed pursuant to a limit order during an open trading window; the reported weighted-average sale price was $480.00 (transactions ranged $480.00–$480.09). After the sale, the reporting person beneficially owned 57,500 shares. The filer notes availability of full pricing detail upon request. No derivative transactions or other changes in beneficial ownership are reported.

Positive

• Transaction executed via limit order during open window, indicating compliance with insider trading policies
• Weighted-average price disclosed with offer to provide full pricing details on request

Negative

• Reported sale of 10,000 shares reduces the reporting person's direct holding, which may be viewed negatively by some investors

Insights

Financial Analyst

TL;DR: Insider sale of 10,000 shares at ~$480 each reduces holdings but appears routine and executed via limit order in open window.

The sale represents a simple disposition rather than option exercise or derivative activity. The weighted-average price reported at $480.00 with a narrow range indicates orderly execution. Post-transaction ownership of 57,500 shares remains disclosed. From a financial perspective this is a routine insider liquidity event with limited immediate implications for company fundamentals.

Corporate Governance Expert

TL;DR: Transaction follows compliance protocols (limit order, open window) and includes standard disclosure; no governance red flags evident.

The filing states the sale was pursuant to a limit order placed during an open trading window and provides a commitment to supply full pricing details on request, which aligns with good disclosure practice. There is no indication of Rule 10b5-1 plan usage on the face of this form. The disclosure appears complete for the reported non-derivative sale.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

BURWIG SUSAN E

(Last) (First) (Middle)

C/O MEDPACE HOLDINGS, INC.

5375 MEDPACE WAY

(Street)

CINCINNATI OH 45227

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Medpace Holdings, Inc. [ MEDP ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	Exec. VP, Operations

3. Date of Earliest Transaction (Month/Day/Year)
09/03/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/03/2025		S(1)		10,000	D	$480(2)	57,500	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The transactions reported on this Form 4 were effected pursuant to a limit order placed by the Reporting Person during an open window period.

2. The reported price is a weighted average price. These shares were sold in multiple transactions ranging from $480.00 to $480.09. The Reporting Person undertakes to provide full pricing information to the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission upon request.

Remarks:

	/s/ Stephen P. Ewald, Attorney-in-Fact for Susan E. Burwig	09/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transaction did Susan E. Burwig report on Medpace (MEDP)?

The filing reports a sale of 10,000 shares of Medpace common stock executed pursuant to a limit order.

At what price were the Medpace shares sold in the Form 4?

The reported weighted-average sale price was $480.00, with individual trades ranging from $480.00 to $480.09.

How many Medpace shares does the reporting person own after the sale?

Following the reported transaction, the reporting person beneficially owned 57,500 shares.

Was the sale part of a Rule 10b5-1 trading plan?

The Form 4 does not indicate that the transaction was made pursuant to a Rule 10b5-1 plan; it states it was executed via a limit order during an open window.

Does the filing disclose derivative activity or option exercises?

No. The form shows only a non-derivative sale of common stock and no derivative securities reported.